九洲药业：关于全资子公司完成工商变更登记的公告

Core Viewpoint - Jiuzhou Pharmaceutical announced a capital increase of 200 million yuan for the construction of an innovative drug CDMO production base in Taizhou, with the project being implemented by Jiuzhou Pharmaceutical (Taizhou) Co., Ltd. [1] Group 1 - The company will hold the 16th meeting of the 8th Board of Directors and the 10th meeting of the 8th Supervisory Board on August 5, 2025 [1] - The capital increase is aimed at supporting the first phase of the construction project [1] - Jiuzhou Pharmaceutical (Taizhou) has completed the business registration change and obtained a new business license from the Market Supervision Administration of Linhai City [1]